{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T02:25:14Z","timestamp":1767925514950,"version":"3.49.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2007,5,23]],"date-time":"2007-05-23T00:00:00Z","timestamp":1179878400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Treat Options Gastro"],"published-print":{"date-parts":[[2007,7]]},"DOI":"10.1007\/s11938-007-0011-5","type":"journal-article","created":{"date-parts":[[2007,5,23]],"date-time":"2007-05-23T17:58:26Z","timestamp":1179943106000},"page":"178-184","source":"Crossref","is-referenced-by-count":17,"title":["Efficacy of infliximab for extraintestinal manifestations of inflammatory bowel disease"],"prefix":"10.1007","volume":"10","author":[{"given":"Benjamin","family":"Siemanowski","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel","family":"Regueiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2007,5,23]]},"reference":[{"key":"11_CR1","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1097\/00005792-197609000-00004","volume":"55","author":"A.J. Greenstein","year":"1976","unstructured":"Greenstein AJ, Janowitz HD, Sachar DB: The extraintestinal complications of Crohn\u2019s disease and ulcerative colitis: a study of 700 patients. Medicine 1976, 55:401\u2013412.","journal-title":"Medicine"},{"key":"11_CR2","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/0016-5085(79)90391-3","volume":"77","author":"G.B. Rankin","year":"1979","unstructured":"Rankin GB, Watts HD, Melynk CS, et al.: National Cooperative Crohn\u2019s Disease Study: extraintestinal manifestations and perianal complications. Gastroenterology 1979, 77:914\u2013920.","journal-title":"Gastroenterology"},{"key":"11_CR3","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/00004836-199607000-00009","volume":"23","author":"F.T. Veloso","year":"1996","unstructured":"Veloso FT, Carvalho J, Magro F: Immune-related systemic manifestations of inflammatory bowel disease. A prospective study of 792 patients. J Clin Gastroenterol 1996, 23:29\u201334.","journal-title":"J Clin Gastroenterol"},{"key":"11_CR4","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.3748\/wjg.v9.i10.2300","volume":"9","author":"L. Lakatos","year":"2003","unstructured":"Lakatos L, Pandur T, David G, et al.: Association of extraintestinal manifestations of inflammatory bowel disease in a province of western Hungary with disease phenotype: results of a 25-year follow-up study. World J Gastroenterol 2003, 9:2300\u20132307.","journal-title":"World J Gastroenterol"},{"key":"11_CR5","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1097\/00054725-200405000-00005","volume":"10","author":"E. Ricart","year":"2004","unstructured":"Ricart E, Panaccione R, Loftus EV, Jr, et al.: Autoimmune disorders and extraintestinal manifestations in first-degree familial and sporadic inflammatory bowel disease: a case-control study. Inflamm Bowel Dis 2004, 10:207\u2013214.","journal-title":"Inflamm Bowel Dis"},{"key":"11_CR6","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1080\/003655201317097173","volume":"36","author":"C. Salvarani","year":"2001","unstructured":"Salvarani C, Vlachonikolis IG, van der Heijde DM, et al.: Musculoskeletal manifestations in a population-based cohort of inflammatory bowel disease patients. Scand J Gastroenterol 2001, 36:1307\u20131313.","journal-title":"Scand J Gastroenterol"},{"key":"11_CR7","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1111\/j.1572-0241.2001.03756.x","volume":"96","author":"C.N. Bernstein","year":"2001","unstructured":"Bernstein CN, Blanchard JF, Rawsthorne P, et al.: The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study. Am J Gastroenterol 2001, 96:1116\u20131122.","journal-title":"Am J Gastroenterol"},{"key":"11_CR8","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1056\/NEJM199710093371502","volume":"337","author":"S.R. Targan","year":"1997","unstructured":"Targan SR, Hanauer SB, van Deventer SJ, et al: A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn\u2019s disease (Crohn\u2019s Disease cA2 Study Group). N Engl J Med 1997, 337:1029\u20131035.","journal-title":"N Engl J Med"},{"key":"11_CR9","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1056\/NEJM199905063401804","volume":"340","author":"D.H. Present","year":"1999","unstructured":"Present DH, Rutgeerts P, Targan S, et al.: Infliximab for the treatment of fistulas in patients with Crohn\u2019s disease. N Engl J Med 1999, 340:1398\u20131405.","journal-title":"N Engl J Med"},{"key":"11_CR10","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S0016-5085(99)70332-X","volume":"117","author":"P. Rutgeerts","year":"1999","unstructured":"Rutgeerts P, D\u2019Haens G, Targan S, et al.: Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn\u2019s disease. Gastroenterology 1999, 117:761\u2013769.","journal-title":"Gastroenterology"},{"key":"11_CR11","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","volume":"359","author":"S.B. Hanauer","year":"2002","unstructured":"Hanauer SB, Feagan BG, Lichtenstein GR, et al.: Maintenance infliximab for Crohn\u2019s disease: the ACCENT I randomized trial. Lancet 2002, 359:1541\u20131549.","journal-title":"Lancet"},{"key":"11_CR12","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1053\/j.gastro.2003.11.014","volume":"126","author":"P. Rutgeerts","year":"2004","unstructured":"Rutgeerts P, Feagan BG, Lichtenstein GR, et al.: Comparison of scheduled and episodic treatment strategies of infliximab in Crohn\u2019s disease. Gastroenterology 2004, 126:402\u2013413.","journal-title":"Gastroenterology"},{"key":"11_CR13","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1056\/NEJMoa030815","volume":"350","author":"B.E. Sands","year":"2004","unstructured":"Sands BE, Anderson FH, Bernstein CN, et al.: Infliximab maintenance therapy for fistulizing Crohn\u2019s disease. N Engl J Med 2004, 350:876\u2013885.","journal-title":"N Engl J Med"},{"key":"11_CR14","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1056\/NEJMoa050516","volume":"353","author":"P. Rutgeerts","year":"2005","unstructured":"Rutgeerts P, Sandborn WJ, Feagan BG, et al.: Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005, 353:2462\u20132476.","journal-title":"N Engl J Med"},{"key":"11_CR15","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1097\/00004836-200607000-00003","volume":"40","author":"S.R. Kethu","year":"2006","unstructured":"Kethu SR: Extraintestinal manifestations of inflammatory bowel disease. J Clin Gastroenterol 2006, 40:467\u2013475.","journal-title":"J Clin Gastroenterol"},{"key":"11_CR16","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1136\/gut.42.3.387","volume":"42","author":"T.R. Orchard","year":"1998","unstructured":"Orchard TR, Wordsworth BP, Jewel DP: Peripheral arthropathies in inflammatory bowel disease: their articular distribution and natural history. Gut 1998, 42:387\u2013391.","journal-title":"Gut"},{"key":"11_CR17","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1016\/S0140-6736(99)05246-0","volume":"354","author":"R. Maini","year":"1999","unstructured":"Maini R, St Clair EW, Breedveld F, et al.: Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999, 354:1932\u20131939.","journal-title":"Lancet"},{"key":"11_CR18","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1056\/NEJM200011303432202","volume":"343","author":"P.E. Lipsky","year":"2000","unstructured":"Lipsky PE, van der Heijde DM, St Clair EW, et al.: Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000, 343:1594\u20131602.","journal-title":"N Engl J Med"},{"key":"11_CR19","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1002\/art.20159","volume":"50","author":"R.N. Maini","year":"2004","unstructured":"Maini RN, Breedveld FC, Kalden JR, et al.: Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum 2004, 50:1051\u20131065.","journal-title":"Arthritis Rheum"},{"key":"11_CR20","doi-asserted-by":"crossref","first-page":"3432","DOI":"10.1002\/art.20568","volume":"50","author":"E.W. St Clair","year":"2004","unstructured":"St Clair EW, van der Heijde DM, Smolen JS, et al.: Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 2004, 50:3432\u20133443.","journal-title":"Arthritis Rheum"},{"key":"11_CR21","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1002\/art.20967","volume":"52","author":"C.E. Antoni","year":"2005","unstructured":"Antoni CE, Kavanaugh A, Kirkham B, et al.: Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum 2005, 52:1227\u20131236.","journal-title":"Arthritis Rheum"},{"key":"11_CR22","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1136\/ard.2004.032268","volume":"64","author":"C. Antoni","year":"2005","unstructured":"Antoni C, Krueger GG, de Vlam K, et al.: Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis 2005, 64:1150\u20131157.","journal-title":"Ann Rheum Dis"},{"key":"11_CR23","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1097\/00124743-200104000-00002","volume":"7","author":"M.H. Ellman","year":"2001","unstructured":"Ellman MH, Hanauer SB, Sitrin M, Cohen RD: Crohn\u2019s disease arthritis treated with infliximab: an open trial in four patients. J Clin Rheumatol 2001, 7:67\u201371.","journal-title":"J Clin Rheumatol"},{"key":"11_CR24","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1111\/j.1572-0241.2002.06064.x","volume":"97","author":"H. Herfarth","year":"2002","unstructured":"Herfarth H, Obermeier F, Andus T, et al.: Improvement of arthritis and arthralgia after treatment with infliximab (Remicade) in a German prospective, open-label, multi-center trial in refractory Crohn\u2019s disease. Am J Gastroenterol 2002, 97:2688\u20132690.","journal-title":"Am J Gastroenterol"},{"key":"11_CR25","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1007\/s00296-004-0467-8","volume":"25","author":"I. Kaufman","year":"2005","unstructured":"Kaufman I, Caspi D, Yeshurun D, et al.: The effect of infliximab on extraintestinal manifestations of Crohn\u2019s disease. Rheumatol Int 2005, 25:406\u2013410.","journal-title":"Rheumatol Int"},{"key":"11_CR26","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1016\/S0140-6736(00)03239-6","volume":"356","author":"F. Bosch Van den","year":"2000","unstructured":"Van den Bosch F, Kruithof E, De Vos M, et al.: Crohn\u2019s disease associated with spondyloarthropathy: effect of TNF-alpha blockade with infliximab on articular symptoms. Lancet 2000, 356:1821\u20131822.","journal-title":"Lancet"},{"key":"11_CR27","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/S0140-6736(02)08215-6","volume":"359","author":"J. Braun","year":"2002","unstructured":"Braun J, Brandt J, Listing J, et al.: Treatment of active ankylosing spondylitis with infliximab: a randomized controlled multicentre trial. Lancet 2002, 359:1187\u20131193.","journal-title":"Lancet"},{"key":"11_CR28","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1002\/art.511","volume":"46","author":"F. Bosch Van den","year":"2002","unstructured":"Van den Bosch F, Kruithof E, Baeten D, et al.: Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondylarthropathy. Arthritis Rheum 2002, 46:755\u2013765.","journal-title":"Arthritis Rheum"},{"key":"11_CR29","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1002\/art.11104","volume":"48","author":"J. Braun","year":"2003","unstructured":"Braun J, Brandt J, Listing J, et al.: Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extension study of a three-month, randomized, placebo-controlled trial. Arthritis Rheum 2003, 48:2224\u20132233.","journal-title":"Arthritis Rheum"},{"key":"11_CR30","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1136\/ard.2004.025130","volume":"64","author":"J. Braun","year":"2005","unstructured":"Braun J, Brandt J, Listing J, et al.: Two-year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis. Ann Rheum Dis 2005, 64:229\u2013234.","journal-title":"Ann Rheum Dis"},{"key":"11_CR31","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1093\/rheumatology\/keh584","volume":"44","author":"J. Braun","year":"2005","unstructured":"Braun J, Baraliakos X, Brandt J, et al.: Persistent clinical response to the anti-TNF-alpha antibody infliximab in patients with ankylosing spondylitis over 3 years. Rheumatology 2005, 44:670\u2013676.","journal-title":"Rheumatology"},{"key":"11_CR32","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1136\/ard.2004.029900","volume":"64","author":"S.N. Nikas","year":"2005","unstructured":"Nikas SN, Alamanos Y, Voulgari PV, et al.: Infliximab therapy in ankylosing spondylitis: an observational study. Ann Rheum Dis 2005, 64:940\u2013942.","journal-title":"Ann Rheum Dis"},{"key":"11_CR33","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1136\/ard.2003.012450","volume":"63","author":"S. Generini","year":"2004","unstructured":"Generini S, Giacomelli R, Fedi R, et al.: Infliximab in spondyloarthropathy associated with Crohn\u2019s disease: an open study on the efficacy of inducing and maintaining remission of musculoskeletal and gut manifestations. Ann Rheum Dis 2004, 63:1664\u20131669.","journal-title":"Ann Rheum Dis"},{"key":"11_CR34","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/0190-9622(92)70059-O","volume":"26","author":"B. Gregory","year":"1992","unstructured":"Gregory B, Ho VC: Cutaneous manifestations of gastrointestinal disorders. Part II. J Am Acad Dermatol 1992, 26:371\u2013383.","journal-title":"J Am Acad Dermatol"},{"key":"11_CR35","first-page":"806","volume":"21","author":"E.A. Krull","year":"1987","unstructured":"Krull EA: Erythema nodosum: a review. Cutis 1987, 21:806\u2013810.","journal-title":"Cutis"},{"key":"11_CR36","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/00005792-200001000-00004","volume":"79","author":"M.L. Bennett","year":"2000","unstructured":"Bennett ML, Jackson JM, Jorizzo JL, et al.: Pyoderma gangrenosum. A comparison of typical and atypical forms with an emphasis on time to remission. Case review of 86 patients from 2 institutions. Medicine (Baltimore) 2000, 79:37\u201346.","journal-title":"Medicine (Baltimore)"},{"key":"11_CR37","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0140-6736(97)10187-8","volume":"351","author":"J.P. Callen","year":"1998","unstructured":"Callen JP: Pyoderma gangrenosum. Lancet 1998, 351:581\u2013585.","journal-title":"Lancet"},{"key":"11_CR38","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1111\/j.1365-2133.1997.tb01568.x","volume":"137","author":"P. Driesch von den","year":"1997","unstructured":"von den Driesch P: Pyoderma gangrenosum: a report of 44 cases with follow-up. Br J Dermatol 1997, 137:1000\u20131005.","journal-title":"Br J Dermatol"},{"key":"11_CR39","first-page":"173","volume":"55","author":"F.C. Powell","year":"1985","unstructured":"Powell FC, Schroeter AL, Su WP, et al.: Pyoderma gangrenosum: a review of 86 patients. Q J Med 1985, 55:173\u2013186.","journal-title":"Q J Med"},{"key":"11_CR40","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1080\/003655202320378338","volume":"37","author":"T. Ljung","year":"2002","unstructured":"Ljung T, Staun M, Grove O, et al.: Pyoderma gangrenosum associated with Crohn\u2019s disease: effect of TNF-alpha blockade with infliximab. Scand J Gastroenterol 2002, 37:1108\u20131110.","journal-title":"Scand J Gastroenterol"},{"key":"11_CR41","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1111\/j.1572-0241.2003.07581.x","volume":"98","author":"M. Regueiro","year":"2003","unstructured":"Regueiro M, Valentine J, Plevy S, et al.: Infliximab for treatment of pyoderma gangrenosum associated with inflammatory bowel disease. Am J Gastroenterol 2003, 98:1821\u20131826.","journal-title":"Am J Gastroenterol"},{"key":"11_CR42","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1136\/gut.2005.074815","volume":"55","author":"T.N. Brooklyn","year":"2006","unstructured":"Brooklyn TN, Dunnill MG, Shetty A, et al.: Infliximab for the treatment of pyoderma gangrenosum: a randomized, double blind, placebo controlled trial. Gut 2006, 55:505\u2013509.","journal-title":"Gut"},{"key":"11_CR43","first-page":"711","volume":"85","author":"U. Monsen","year":"1990","unstructured":"Monsen U, Sorstad J, Hellers G, Johansson C: Extracolonic diagnoses in ulcerative colitis: an epidemiological study. Am J Gastroenterol 1990, 85:711\u2013716.","journal-title":"Am J Gastroenterol"},{"key":"11_CR44","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/S0161-6420(03)00721-8","volume":"111","author":"C.C. Murphy","year":"2004","unstructured":"Murphy CC, Ayliffe WH, Booth A, et al.: Tumor necrosis factor alpha blockade with infliximab for refractory uveitis and scleritis. Ophthalmology 2004, 111:352\u2013356.","journal-title":"Ophthalmology"},{"key":"11_CR45","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1038\/sj.eye.6701689","volume":"19","author":"J.M. Benitez-del-Castillo","year":"2005","unstructured":"Benitez-del-Castillo JM, Martinez-de-la-Casa JM, Pato-Cour E, et al.: Long-term treatment of refractory posterior uveitis with anti-TNFalpha (infliximab). Eye 2005, 19:841\u2013845.","journal-title":"Eye"},{"key":"11_CR46","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1001\/archopht.123.7.903","volume":"123","author":"E.B. Suhler","year":"2005","unstructured":"Suhler EB, Smith JR, Wertheim MS, et al.: A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes. Arch Ophthalmol 2005, 123:903\u2013912.","journal-title":"Arch Ophthalmol"},{"key":"11_CR47","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1111\/j.1572-0241.2002.05514.x","volume":"97","author":"W. Fries","year":"2002","unstructured":"Fries W, Giofre MR, Catanoso M, Lo Gullo R: Treatment of acute uveitis associated with Crohn\u2019s disease and sacroileitis with infliximab. Am J Gastroenterol 2002, 97:499\u2013500.","journal-title":"Am J Gastroenterol"},{"key":"11_CR48","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1055\/s-2008-1040541","volume":"8","author":"E. Schrumpf","year":"1988","unstructured":"Schrumpf E, Fausa O, Elgjo K, et al.: Hepatobiliary complications of inflammatory bowel disease. Semin Liver Dis 1988, 8:201\u2013209.","journal-title":"Semin Liver Dis"},{"key":"11_CR49","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/0016-5085(91)70019-T","volume":"100","author":"R. Olsson","year":"1991","unstructured":"Olsson R, Danielsson A, Jarnerot G, et al.: Prevalence of primary sclerosing cholangitis in patients with ulcerative colitis. Gastroenterology 1991, 100:1319\u20131323.","journal-title":"Gastroenterology"},{"issue":"4Suppl1","key":"11_CR50","doi-asserted-by":"crossref","first-page":"A526","DOI":"10.1016\/S0016-5085(03)82662-8","volume":"124","author":"M. Regueiro","year":"2003","unstructured":"Regueiro M, Chopra K, Slivka A: Improvement of liver function tests in patients with primary sclerosing cholangitis and Crohn\u2019s disease treated with infliximab [abstract]. Gastroenterology 2003, 124(4 Suppl 1):A526.","journal-title":"Gastroenterology"}],"container-title":["Current Treatment Options in Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11938-007-0011-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11938-007-0011-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11938-007-0011-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,22]],"date-time":"2020-04-22T07:49:11Z","timestamp":1587541751000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11938-007-0011-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,5,23]]},"references-count":50,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2007,7]]}},"alternative-id":["11"],"URL":"https:\/\/doi.org\/10.1007\/s11938-007-0011-5","relation":{},"ISSN":["1092-8472","1534-309X"],"issn-type":[{"value":"1092-8472","type":"print"},{"value":"1534-309X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,5,23]]}}}